In recent years, tremendous excitement and development has taken place involving lutetium-177-labeled pharmaceuticals targeting prostate-specific membrane antigens (177Lu-PSMA RPTs), having demonstrated promising outcomes in terms of tumor response and overall survival [4,5]. This evidence concerns the gene FOLH1 and neoplasm.